REVERSIR Trademark Information

Trademark by Alnylam Pharmaceuticals, Inc.

Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, al...

Classification Information

Intent to Use Trademark - Applicant has not submitted proof of use in commerce the the USPTO.

Primary Class: Class Details:
Class (005)
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
First Use Anywhere:: Not provided
First Use In Commerce: Not provided
General Information
Word mark: REVERSIR
Status/Status Date:
ABANDONED - AFTER PUBLICATION
3/29/2022
Serial Number: 90696853
Filing Date: 5/7/2021
Registration Number: NOT AVAILABLE
Registration Date: NOT AVAILABLE
Goods and Services: Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection
Mark Description: NOT AVAILABLE
Type Of Mark: TradeMark
Published For Opposition Date: 1/25/2022
Last Applicant/Owner:
Alnylam Pharmaceuticals, Inc.
********
********
***** ****
Mark Drawing Code: Standard Character Mark
Design Search:
(NO DATA)
Register Type: Principal
Disclaimer: (NOT AVAILABLE)
Correspondent:
********
********
***** ****
Current Status:
ABANDONED - AFTER PUBLICATION
3/29/2022
Correspondent Search:
Alnylam Pharmaceuticals, Inc. is a correspondent of REVERSIR trademark.
Current Overall Rating:
RatingRatingRatingRatingRating

(0 review)

As seen on